Highest quality protein library

A more comprehensive screen

Human cell microarray technology has long been the leading tool for discovering primary receptors and assessing potential off-target binding against expressed human proteins. Over a decade of continual development has ensured that the Retrogenix library is of the highest quality. Initially representing only plasma membrane monomers, the Retrogenix library now, uniquely, includes cell surface heterodimers as well as secreted proteins that have been identified as key off-targets for screening through our close collaborations with toxicology teams at leading pharmaceutical companies. Our rigorous bioinformatics approach ensures that miscategorised proteins are always excluded from our library, safeguarding the specificity of our results and providing clients with the confidence that real targets will discovered and won’t be masked by a raft of false positives.

Building the best

After > 10 years of expansion and refinement, the Retrogenix cell microarray libraries currently have >6,200 proteins for screening. This is the largest set of plasma membrane and secreted proteins expressed in human cells. As data from our specificity screens are frequently used to support IND / BLA submissions it is crucial that we always ensure our technology retains its high success rates as our capabilities continue to grow. The high degree of confidence that clients have when assessing the specificity of a novel biotherapeutic or cell therapy using Retrogenix has allowed many of them to move away from tissue cross reactivity studies altogether.

Tethering ‘secreted’ proteins

As secreted proteins are not naturally localised on the cell surface, novel cDNA constructs have been developed which result in expression of ‘secreted’ proteins fused to inert transmembrane and intracellular domains. As these proteins are tethered to the membrane, binding can be detected using the same workflow as the plasma membrane library. Our bioinformatics collaboration on this project resulted in a ‘high confidence’ list of secreted proteins being generated, for priority inclusion in the library. Of these, >75% are now expressed in the Retrogenix collection, with more under development. Extensive testing and validation work has confirmed that binding of known ligand:secreted protein pairs can be identified consistently using Retrogenix. Retrogenix continues to innovate and develop its technology to broaden the applications of its platform and provide valuable data that informs both Discovery and safety assessment.

Read our case study for more details of how the tethered secreted library has been developed and tested.

See case study

Download our poster: “Screening the secretome for off-target binding using  human cell microarray technology.”

Download poster

Find out how our specificity screening data are used in IND / BLA submissions Regulatory submissions

Simcere logo
Aveo Oncology - The Human Response
Theraclone Sciences
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
Sanofi Logo
The University of Copenhagen
Lund University
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
The University of Sheffield
Capella Bioscience Logo
Unum Theraputics Logo
Celyad Logo
We were impressed with the power of the Retrogenix technology in terms of on/off target characterization of early drug candidates. Their quick turnaround time and excellent, proactive communication was a real pleasure.
Dr. Bernd Schlereth, Senior Director Nonclinical Safety, Covagen